- Report
- October 2024
- 197 Pages
Global
From €3371EUR$3,545USD£2,834GBP
€3745EUR$3,939USD£3,149GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Report
- December 2024
- 150 Pages
Global
From €3756EUR$3,950USD£3,158GBP
- Report
- February 2025
- 200 Pages
Global
From €4269EUR$4,490USD£3,590GBP
- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1189EUR$1,250USD£999GBP
- Report
- August 2024
- 150 Pages
Global
From €2652EUR$2,789USD£2,230GBP
- Report
- January 2023
- 150 Pages
United States
From €3756EUR$3,950USD£3,158GBP
- Report
- July 2021
- 50 Pages
China
From €2472EUR$2,600USD£2,079GBP
- Report
- March 2024
- 164 Pages
Global
From €7559EUR$7,950USD£6,356GBP
- Drug Pipelines
- December 2022
- 30 Pages
Global
From €3090EUR$3,250USD£2,598GBP
- Report
- February 2024
- 204 Pages
Global
From €4516EUR$4,750USD£3,798GBP
- Report
- January 2022
- 121 Pages
Global
From €4516EUR$4,750USD£3,798GBP
- Report
- May 2023
- 114 Pages
Global
From €3500EUR$3,943USD£3,046GBP
- Report
- January 2025
- 93 Pages
Global
From €3500EUR$3,943USD£3,046GBP
- Report
- March 2025
- 50 Pages
Global
From €2520EUR$2,650USD£2,119GBP
- Report
- August 2024
- 199 Pages
China
From €3803EUR$4,000USD£3,198GBP
- Report
- August 2024
- 98 Pages
China
From €1711EUR$1,800USD£1,439GBP
- Report
- July 2024
- 280 Pages
Global
From €2524EUR$2,655USD£2,123GBP

Capecitabine is a chemotherapy drug used to treat non-small cell lung cancer (NSCLC). It is a type of oral chemotherapy, meaning it is taken in pill form. Capecitabine works by blocking the growth of cancer cells and preventing them from dividing and spreading. It is often used in combination with other chemotherapy drugs to increase the effectiveness of treatment. Capecitabine is generally well-tolerated, with fewer side effects than other chemotherapy drugs.
Capecitabine is a relatively new drug, first approved by the FDA in 1998. It is now widely used in the treatment of NSCLC, and is often prescribed in combination with other chemotherapy drugs. It is also used to treat other types of cancer, such as breast cancer and colorectal cancer.
In the Capecitabine market, some of the major players include Roche, Pfizer, Merck, AstraZeneca, and Bristol-Myers Squibb. These companies manufacture and distribute the drug, as well as provide support services to healthcare providers and patients. Show Less Read more